A Phase I/II, Single-center, Randomized Double Masked Placebo Controlled Study to Evaluate the Safety and Efficacy of Treatment With AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)
Phase of Trial: Phase I/II
Latest Information Update: 08 Aug 2018
At a glance
- Drugs AS 101 (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- 08 Jan 2018 Planned End Date changed from 1 Dec 2018 to 1 Mar 2019.
- 08 Jan 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Jan 2019.
- 08 Jan 2018 Status changed from not yet recruiting to recruiting.